Multiple Myeloma
Multiple Myeloma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
43
Clinical Trials
Multiple Myeloma
N/A
Enrolling
nct/study# NCT05332054 / CARIBOU-LTFS
An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / CART-APHERESIS-OUTCOMES
Real World Outcomes of Patients who underwent apheresis for CAR-T
Learn More
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT05722418 / CB11A
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / CHECKPOINT-INHIBITOR
Analysis of Checkpoint Inhibitors as Post-Transplant Consolidation in Relapsed/Refractory and High-Risk Multiple Myeloma
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# NCT03435796 / GC-LTFU-001
Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T-Cells
Learn More
Multiple Myeloma
Phase III
Enrolling
nct/study# NCT06679101 / GSK-214828
A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)-DREAMM-10
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.